Critical Reviews in Clinical Laboratory Sciences,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 17
Published: June 7, 2024
Pulmonary
arterial
hypertension
(PAH),
one
subtype
of
pulmonary
(PH),
is
a
life-threatening
condition
characterized
by
remodeling,
elevated
vascular
resistance,
and
blood
pressure
in
the
arteries,
leading
to
right
heart
failure
increased
mortality.
The
disease
marked
endothelial
dysfunction,
vasoconstriction,
remodeling.
role
Sodium-Glucose
Co-Transporter-2
(SGLT2)
inhibitors,
class
medications
originally
developed
for
diabetes
management,
increasingly
being
explored
context
cardiovascular
diseases,
including
PAH,
due
their
potential
modulate
these
pathophysiological
processes.
In
this
review,
we
systematically
examine
burgeoning
evidence
from
both
basic
clinical
studies
that
describe
effects
SGLT2
inhibitors
on
health,
with
special
emphasis
PAH.
By
delving
into
complex
interactions
between
drugs
pathobiology
underpins
PH,
study
seeks
uncover
mechanistic
underpinnings
could
justify
use
as
novel
therapeutic
approach
We
collate
findings
illustrate
how
may
influence
normal
function
possibly
alleviating
pathological
hallmarks
PAH
such
inflammation,
oxidative
stress,
aberrant
cellular
proliferation,
so
on.
Our
review
thereby
outlines
paradigm
shift
suggesting
play
crucial
modulating
disease's
progression
targeting
dysfunctions
drive
it.
This
comprehensive
synthesis
existing
research
underscores
imperative
need
further
trials
validate
efficacy
integrate
them
agents
used
against
challenging
disease.
New England Journal of Medicine,
Journal Year:
2024,
Volume and Issue:
390(15), P. 1394 - 1407
Published: March 28, 2024
Obesity
and
type
2
diabetes
are
prevalent
in
patients
with
heart
failure
preserved
ejection
fraction
characterized
by
a
high
symptom
burden.
No
approved
therapies
specifically
target
obesity-related
persons
diabetes.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(1), P. 27 - 40
Published: May 13, 2024
The
glucagon-like
peptide-1
receptor
agonist,
semaglutide,
improved
health
status
and
reduced
body
weight
in
patients
with
obesity-related
heart
failure
(HF)
preserved
ejection
fraction
(HFpEF)
the
STEP-HFpEF
Program.
Whether
benefits
were
due
to
mechanical
unloading
or
effects
on
HF
pathobiology
is
uncertain.
Determine
if
semaglutide
2.4
mg
N-terminal
pro-brain
natriuretic
peptide
(NTproBNP)
HFpEF
compare
treatment
responses
by
baseline
NTproBNP.
Prespecified
secondary
analysis
of
pooled
data
from
two
double-blind,
placebo-controlled,
randomized
trials
(STEP-HFpEF
DM)
testing
HFpEF.
main
outcomes
change
NTproBNP
at
52
weeks
dual
primary
endpoints
KCCQ-CSS
1145
randomized.
Semaglutide,
compared
placebo,
(estimated
ratio
0.82
[95%
CI:
0.74-;
0.91];
P
=
0.0002).
Improvements
more
pronounced
those
higher
vs
lower
difference:
tertile
1:
4.5
points
0.8–8.2],
2:
6.2
2.4–10.0],
3:
11.9
8.1–15.7];
interaction
0.02;
as
a
continuous
variable:
0.004).
Reductions
consistent
across
levels
(interaction
0.21).
In
HFpEF,
Participants
had
similar
degree
loss
but
experienced
larger
reductions
HF-related
symptoms
physical
limitations
than
European Heart Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 13, 2025
Journal
Article
Dapagliflozin
and
ventilatory
control
during
exercise
in
heart
failure
with
preserved
ejection
fraction:
the
CAMEO-DAPA
trial
Get
access
Shunichi
Doi,
Doi
Department
of
Cardiovascular
Disease,
Mayo
Clinic,
200
First
Street
SW,
Rochester,
MN
55905,
USA
Search
for
other
works
by
this
author
on:
Oxford
Academic
PubMed
Google
Scholar
Yogesh
N
V
Reddy,
Reddy
Michael
D
Jensen,
Jensen
Joshua
R
Smith,
Smith
Barry
A
Borlaug
Corresponding
author.
Tel:
+507
284
4442,
Fax:
266
0228,
Email:
[email
protected]
https://orcid.org/0000-0001-9375-0596
European
Heart
Journal,
ehaf027,
https://doi.org/10.1093/eurheartj/ehaf027
Published:
19
February
2025
history
Received:
08
November
2024
Revision
received:
05
December
Accepted:
15
January
JAMA Cardiology,
Journal Year:
2024,
Volume and Issue:
9(9), P. 843 - 843
Published: July 24, 2024
Increases
in
pulmonary
capillary
wedge
pressure
(PCWP)
during
exercise
reduce
artery
(PA)
compliance,
increase
pulsatile
right
ventricular
(RV)
afterload,
and
impair
RV-PA
coupling
patients
with
heart
failure
preserved
ejection
fraction
(HFpEF).
The
effects
of
the
sodium-glucose
cotransporter
2
(SGLT2)
inhibitor
dapagliflozin
on
vascular
properties
are
unknown.
Circulation,
Journal Year:
2024,
Volume and Issue:
150(13), P. 997 - 1009
Published: Aug. 5, 2024
BACKGROUND:
Systemic
arterial
compliance
and
venous
capacitance
are
typically
impaired
in
patients
with
heart
failure
preserved
ejection
fraction
(HFpEF),
contributing
to
hemodynamic
congestion
stress.
Sodium-glucose
cotransporter-2
inhibitors
reduce
improve
clinical
outcomes
HFpEF,
but
the
mechanisms
remain
unclear.
This
study
tested
hypothesis
that
Dapagliflozin
would
systemic
during
exercise
HFpEF.
METHODS:
In
this
secondary
analysis
from
CAMEO-DAPA
trial
(Cardiac
Metabolic
Effects
of
Heart
Failure
With
Preserved
Ejection
Fraction
Trial),
37
HFpEF
(mean
age
68
±
9
years,
women
65%)
underwent
invasive
testing
simultaneous
echocardiography
at
baseline
following
treatment
for
24
weeks
or
placebo.
Radial
artery
pressure
(BP)
was
measured
continuously
using
a
fluid-filled
catheter
transformation
aortic
pressure,
central
hemodynamics
were
high-fidelity
micromanometers,
stressed
blood
volume
estimated
indices
fit
comprehensive
cardiovascular
model.
RESULTS:
There
no
statistically
significant
effect
on
resting
BP,
reduced
systolic
BP
peak
(estimated
difference
[ETD],
−18.8
mm
Hg
[95%
CI,
−33.9
−3.7]
P
=0.016).
Reduction
related
improved
exertional
total
(ETD,
0.06
mL/mm
Hg/m
2
0.003–0.11]
=0.039)
root
characteristic
impedance
−2.6
Hg/mL*sec
CI:
−5.1
−0.03]
=0.048),
vascular
resistance.
rest
−292
−530
−53]
=0.018),
evidenced
by
decline
ratio
−7.3%
−13.3
−1.3]
=0.020).
Each
these
effects
also
observed
matched
20W
intensity.
Improvements
correlated
decreases
body
weight,
reduction
change
(r=0.40,
=0.019).
Decreases
pulmonary
capillary
wedge
(r=0.56,
<0.001).
CONCLUSIONS:
exercise,
while
reducing
impedance,
suggesting
wall
stiffness.
These
may
partially
explain
benefits
sodium-glucose
REGISTRATION:
URL:
https://www.clinicaltrials.gov
;
Unique
identifier:
NCT04730947.
